Introduction
MULTIPLE SCLEROSIS (MS), DISEASE
Treatment for multiple sclerosis (MS) often requires routine and long‐term care for optimal disease management, including the administration of disease‐modifying therapies (DMTs) by intravenous (IV) infusion.Ocrelizumab is a recombinant, humanized monoclonal antibody that selectively targets CD20‐expressing B cells and is approved for the treatment of both relapsing (RMS) and primary progressive (PPMS) forms of MS.A number of recent clinical studies have evaluated the safety of shorter infusion times for patients with MS who received ocrelizumab treatment.The safety and benefit of the reduced infusion time for ocrelizumab has been established; however, limited data are available for the safety of home‐based infusions, especially in MS. The aim of this study was to develop and investigate a feasible and safe home infusion model, as well as to gain insights into the patient experience, for those who receive at‐home infusions of ocrelizumab and are monitored by telehealth visits for translation into routine clinical practice.